EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 613 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Newest Gerber Baby is Child of Breast Cancer Survivor June 29, 2021 Scientists Link a Single Type of Bacteria to Colorectal Cancer April 19, 2024 Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast... January 14, 2021 FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... February 21, 2025 Load more HOT NEWS An apple a day keeps the doctor away Five-Year Outcomes with CAR T Cell Therapy Dad Sings “Ave Maria” For His Daughter At Disney World Taking pride in all of our researchers
